Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer

Journal article published in 2022 by Andreas Schneeweiss, Laura L. Michel, Volker Möbus , Hans Tesch, Peter Klare, Eric Hahnen, Carsten Denkert, Karin Kast, Esther Pohl-Rescigno, Claus Hanusch, Theresa Link, Michael Untch, Christian Jackisch , Jens-Uwe Blohmer , Peter A. Fasching  and other authors. Andreas Schneeweiss, Laura L. Michel, Volker Möbus , Hans Tesch, Peter Klare, Eric Hahnen, Carsten Denkert, Karin Kast, Esther Pohl-Rescigno, Claus Hanusch, Theresa Link, Michael Untch, Christian Jackisch , Jens-Uwe Blohmer , Peter A. Fasching , Christine Solbach, Rita K. Schmutzler, Jens Huober, Kerstin Rhiem, Valentina Nekljudova , Kristina Lübbe, Sibylle Loibl 

Show less

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by